Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 41.3 USD
Weaknesses
  • With an enterprise value anticipated at 3.56 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES13.62%75 410
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
SANOFI12.63%121 897
BAYER AG14.60%107 831
GLAXOSMITHKLINE PLC-0.77%98 661
BRISTOL-MYERS SQUIBB CO-4.09%92 339
ELI LILLY AND CO11.57%90 541
Autres valeurs du secteur
Company
Engages in the discovery, development, manufacture and sale of health care productsAbbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products.It operates through the following segments: Established Pharmaceutical Products,... 
Sector
Pharmaceuticals
Calendar
07/19Earnings Release
More about the company
Advertisement
Financials ($)
Sales 2017 26 357 M
EBIT 2017 5 879 M
Net income 2017 3 106 M
Debt 2017 18 313 M
Yield 2017 2,40%
P/E ratio 2017 24,54
P/E ratio 2018 18,96
EV / Sales 2017 3,56x
EV / Sales 2018 3,30x
Capitalization 75 410 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period : Day
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Duration : Period : Week
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Surperformance© ratings  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
More Ratings